A new targeting approach for breast cancer gene therapy using the human fatty acid synthase promoter.
Gene therapy with adenoviral vectors is a promising new approach for the treatment of refractory advanced breast cancer. Strategies to restrict adenoviral-mediated therapeutic gene expression are important to avoid harming normal cells. Fatty acid synthase (FAS) is overexpressed in several human cancers. FAS is highly expressed in infiltrating breast cancer tissue, and always associated with malignant phenotypes and poor prognosis. In this study, expression of the FAS was evaluated in three breast cancer cell lines. A 680 bp-FAS promoter was cloned and its transcriptional activity was analyzed in breast cancer cell lines. We made a recombinant adenovirus construct carrying herpes simplex virus thymidine kinase (HSV-TK) driven by human FAS promoter (Ad-FAS-TK) and analyzed its target cytotoxicity in vitro and in vivo against human breast cancer cells combined with prodrug ganciclovir (GCV). The results show that the expression of FAS varies in the three breast cancer cell lines examined (respectively, SK-Br3>MCF-7>MDA-MB-231), but FAS promoter can initiate relative high transcriptional activities in all three kinds of cancer cells while little in normal fibroblast cells. Furthermore, FAS promoter can drive the therapeutic gene in a wider range of human breast cancers than cerbB2 promoter and exhibit a stronger activity than midkine (MK) promoter. Combination of Ad-FAS-TK and GCV treatment exhibited strong-targeted cytotoxic effect on breast cancer cells but showed little activity in normal fibroblast cells. The tumorigenic capability of breast cancer cells treated with Ad-FAS-TK/GCV was completely inhibited in vitro and in vivo assays. In conclusion, adenoviral-mediated suicide gene therapy controlled by tumor associated-FAS promoter can induce specific cytotoxic effect on human breast cancer cells in vitro and in vivo. So it is a promising target for the development of gene therapy against breast cancers.
Yan
Chen
C
Department of Clinical Oncology, Xi'jing Hospital, Fourth Military Medical University (FMMU), Xi'An, China.
Wen-Chao
Liu
L
Hong-Yan
Qin
Q
Rui
Zhang
Z
Wei-Lin
Jin
J
Hua
Han
H
D000260:Adenoviruses, Human; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy; D004268:DNA-Binding Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D064429:Fatty Acid Synthases / Q000187:drug effects / Q000627:therapeutic use*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D015870:Gene Expression; D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D066298:In Vitro Techniques; D009687:Nuclear Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D010641:Phenotype; D011379:Prognosis; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D011993:Recombinant Fusion Proteins; D025521:Tumor Suppressor Proteins; D064429:Fatty Acid Synthases; D015774:Ganciclovir